ArticleChemistry (Weinheim an der Bergstrasse, Germany)2020
Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB
Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Structural basis for positive allosteric regulation of CB2 receptor.Nature communications · 2026Article
- Cannabidiol at Nanomolar Concentrations Negatively Affects Signaling through the Adenosine AInternational journal of molecular sciences · 2023Article
- New Insights into Bitopic Orthosteric/Allosteric Ligands of Cannabinoid Receptor Type 2.International journal of molecular sciences · 2023Article
- A Single Point Mutation Blocks the Entrance of Ligands to the Cannabinoid CBJournal of chemical information and modeling · 2022Article
- Regulation of Expression of Cannabinoid CBInternational journal of molecular sciences · 2022Article
- Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.Journal of medicinal chemistry · 2022Article
- Covalent cannabinoid receptor ligands - structural insight and selectivity challenges.RSC medicinal chemistry · 2022Review
- Heterobivalent Ligand for the Adenosine AJournal of medicinal chemistry · 2022Article
- Modulating brain integrative actions as a new perspective on pharmacological approaches to neuropsychiatric diseases.Frontiers in endocrinology · 2022Review
- The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CBFrontiers in pharmacology · 2022Review
- N-Methyl-D-aspartate (NMDA) and cannabinoid CBAlzheimer's research & therapy · 2021Article
- Orthosteric and Allosteric Dual Targeting of the Nuclear Receptor RORγt with a Bitopic Ligand.ACS chemical biology · 2021Article
- Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CBChemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Single chemical entities with potential to simultaneously interact with two binding sites are emerging strategies in medicinal chemistry. We have designed, synthesized and functionally characterized the first bitopic ligands for the CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.